2011 Press Releases

DateTitle 
November 28, 2011POZEN Monetizes Its Treximet Royalty Stream for $75 MillionPrinter Friendly Version
November 17, 2011POZEN to Present at the Piper Jaffray 23rd Annual Healthcare ConferencePrinter Friendly Version
November 14, 2011Positive Results from POZEN Phase 1 Study ("Co-Rx") Presented At AHAPrinter Friendly Version
November 09, 2011Pozen to Present at the Lazard Capital Markets' 8th Annual Healthcare ConferencePrinter Friendly Version
November 08, 2011POZEN To Participate in the Brean Murray Carret & Co. 2011 Life Sciences SummitPrinter Friendly Version
November 03, 2011POZEN Reports Third Quarter 2011 ResultsPrinter Friendly Version
October 20, 2011POZEN Announces November 3, 2011 Webcast of Third Quarter 2011 ResultsPrinter Friendly Version
October 13, 2011POZEN Reports Top-Line Data from Long-Term Safety Study of PA32540Printer Friendly Version
October 04, 2011POZEN Provides Patent Litigation and Financial Guidance UpdatePrinter Friendly Version
October 03, 2011POZEN Announces Engaging Keelin Reeds Partners LLC to Assist With PA32540 Strategic Partner SearchPrinter Friendly Version
September 27, 2011POZEN Announces October 4, 2011 Mid-Quarter Update and Financial Guidance WebcastPrinter Friendly Version
September 08, 2011POZEN To Present at the 2011 UBS Global Life Sciences ConferencePrinter Friendly Version
August 24, 2011POZEN to Present at the 2011 Stifel Nicolaus Healthcare ConferencePrinter Friendly Version
August 16, 2011POZEN Welcomes Clint Burrus as Vice President, Customer DevelopmentPrinter Friendly Version
August 08, 2011Pozen Patents Upheld in Treximet Patent LitigationPrinter Friendly Version
July 28, 2011POZEN Reports Second Quarter 2011 ResultsPrinter Friendly Version
July 27, 2011POZEN Welcomes Dr. Seth A. Rudnick to the Board of DirectorsPrinter Friendly Version
July 19, 2011POZEN Forms Unprecedented Advisory Board of Digital Thought-Leaders to Advance Commercial PlansPrinter Friendly Version
July 14, 2011POZEN Announces July 28, 2011 Webcast of Second Quarter 2011 ResultsPrinter Friendly Version
July 12, 2011POZEN Announces Tomas S. Bocanegra, M.D. as Head of DevelopmentPrinter Friendly Version
June 16, 2011POZEN Announces Election of Dr. Martin Nicklasson to the Board of DirectorsPrinter Friendly Version
June 15, 2011POZEN to Present at The UBS Specialty Pharmaceuticals ConferencePrinter Friendly Version
June 09, 2011POZEN to Present at the 2011 Wells Fargo Securities Healthcare ConferencePrinter Friendly Version
May 25, 2011POZEN Ranked as Second Most Efficient Pharma Company by SmarTrendPrinter Friendly Version
May 24, 2011POZEN to Present at the Jefferies 2011 Global Life Sciences ConferencePrinter Friendly Version
May 05, 2011POZEN Reports First Quarter 2011 ResultsPrinter Friendly Version
April 25, 2011AstraZeneca and POZEN File Patent Infringement Lawsuit Against Dr. Reddy'sPrinter Friendly Version
April 21, 2011POZEN Announces May 5, 2011 Webcast of First Quarter 2011 ResultsPrinter Friendly Version
April 15, 2011Preliminary Injunction Ordered in POZEN Treximet Patent LitigationPrinter Friendly Version
March 24, 2011POZEN To Present at the 10th Annual Needham Healthcare ConferencePrinter Friendly Version
March 24, 2011POZEN Reports Superior Platelet Inhibition of PA32540 Regimen Over a Standard of Care Regimen in a Phase 1 Study ("Co-Rx")Printer Friendly Version
March 23, 2011POZEN Announces Licensing Deal with Cilag GmbH, A Division of Johnson & Johnson, for MT 400, Migraine TreatmentPrinter Friendly Version
March 22, 2011POZEN Files Motion for Preliminary Injunction in Treximet Patent LitigationPrinter Friendly Version
March 09, 2011POZEN Reports Fourth Quarter and Year End 2010 ResultsPrinter Friendly Version
February 24, 2011POZEN Announces March 9, 2011 Webcast of Fourth Quarter & Year End 2010 ResultsPrinter Friendly Version
February 23, 2011POZEN to Present at the Cowen and Company 31st Annual Healthcare ConferencePrinter Friendly Version
February 22, 2011POZEN Announces Addition to Commercial TeamPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.